Janssen Pharmaceuticals

May 15, 2020May 15, 2020

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

News

Adding Erleada (apalutamide) to androgen deprivation therapy (ADT) significantly extends the lives of men with non-metastatic castration-resistant prostate cancer (CRPC) by more than one year, a final analysis of the SPARTAN ... Read more

July 17, 2019

TRC253 Showing Effectiveness in Metastatic Castration-resistant Prostate Cancer Patients

News

The potential oral therapy TRC253 was well-tolerated and showed effectiveness in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the first part of a Phase ... Read more

February 19, 2018February 19, 2018

Health Canada Approves New Indication for Zytiga for Treatment of Hormone-Sensitive Prostate Cancer

News

Health Canada recently approved Zytiga (abiraterone acetate) in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) ... Read more

February 14, 2018February 14, 2018

FDA Approves Zytiga Plus Prednisone for Earlier Form of Metastatic Prostate Cancer

News

Zytiga (abiraterone acetate) is now approved in the U.S. to treat metastatic high-risk castration-sensitive prostate cancer (CSPC) in combination with prednisone, Janssen Pharmaceutical Companies announced. The U.S. Food and Drug ... Read more

December 19, 2017December 19, 2017

Genomic Health, Janssen Partner to Advance Test Predicting Best Treatment for Low-Risk Prostate Cancer

News

Genomic Health announced has entered a multi-year agreement with Janssen Pharmaceuticals to evaluate its genomic expression test intended to aid in the treatment of recently diagnosed and low-risk prostate cancer patients. As ... Read more